How Will We Pay For Miracle Cures?

The video discusses the potential of gene therapy treatments for sickle cell anemia, highlighting the challenges of making these treatments accessible and affordable. It covers the treatment process, cost implications, and the roles of various stakeholders in addressing these issues. The economic impact on public insurers and the need for innovative payment models are also explored, emphasizing the importance of ensuring that new therapies reach those in need.

What is the primary goal of the gene therapy treatment for sickle cell anemia?

• To create new types of blood cells

• To increase the number of red blood cells

• To replace unhealthy cells with healthy ones

• To eliminate the need for blood transfusions

What is a major financial concern regarding the availability of gene therapy treatments?

• The treatments are not effective

• The treatments are too time-consuming

• The treatments are too expensive

• The treatments require frequent administration

How might state Medicaid budgets be affected by the introduction of gene therapy treatments?

• They may become more flexible

• They may experience a surplus

• They may face cuts in other areas

• They may eliminate other treatments

What is a potential long-term benefit of gene therapy for patients?

• Increased dependency on medication

• Improved quality of life and work opportunities

• Reduced need for medical innovation

• Higher healthcare costs

What is a key factor in ensuring the success and accessibility of gene therapy treatments?

• Developing more complex treatments

• Limiting the number of patients treated

• Increasing the cost of treatments

• Creating a sustainable payment model